Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Illumina, Inc.
Illumina, Inc. News
Illumina, Inc. Quantitative Score
About Illumina, Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
Illumina, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Illumina, Inc. Financials
Table Compare
Compare ILMN metrics with: | |||
|---|---|---|---|
Earnings & Growth | ILMN | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ILMN | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ILMN | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ILMN | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Illumina, Inc. Income
Illumina, Inc. Balance Sheet
Illumina, Inc. Cash Flow
Illumina, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Buy |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Illumina, Inc. Executives
| Name | Role |
|---|---|
| Mr. Jacob Thaysen Ph.D. | Chief Executive Officer & Director |
| Mr. Ankur Dhingra CPA | Chief Financial Officer |
| Dr. Steven Barnard Ph.D. | Chief Technology Officer |
| Mr. Kevin Carl Pegels | Chief of Global Operations |
| Mr. Scott Ericksen | Vice President & Chief Accounting Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Jacob Thaysen Ph.D. | Chief Executive Officer & Director | Male | 1975 | 2.5M |
| Mr. Ankur Dhingra CPA | Chief Financial Officer | Male | 1976 | 1.85M |
| Dr. Steven Barnard Ph.D. | Chief Technology Officer | 1961 | 974.91K | |
| Mr. Kevin Carl Pegels | Chief of Global Operations | Male | 1968 | 921.04K |
| Mr. Scott Ericksen | Vice President & Chief Accounting Officer | Male | 1973 | -- |
Illumina, Inc. Insider Trades
| Date | 12 Nov |
| Name | Davies Scott M |
| Role | Chief Legal Officer |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 323 |
| Date | 5 Nov |
| Name | Davies Scott M |
| Role | Chief Legal Officer |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 398 |
| Date | 5 Nov |
| Name | Ericksen Scott D |
| Role | VP, Chief Accounting Officer |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 206 |
| Date | 5 Nov |
| Name | Leckman Patricia |
| Role | SVP, Chief People Officer |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 296 |
| Date | 5 Nov |
| Name | Pegels Kevin Carl |
| Role | Chief of Global Operations |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 599 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 12 Nov | Davies Scott M | Chief Legal Officer | Disposed | D-Return | 323 |
| 5 Nov | Davies Scott M | Chief Legal Officer | Disposed | F-InKind | 398 |
| 5 Nov | Ericksen Scott D | VP, Chief Accounting Officer | Disposed | F-InKind | 206 |
| 5 Nov | Leckman Patricia | SVP, Chief People Officer | Disposed | F-InKind | 296 |
| 5 Nov | Pegels Kevin Carl | Chief of Global Operations | Disposed | F-InKind | 599 |